Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.

Dutta D, Kamrul-Hasan ABM, Jindal R, Mohindra R, Mohindra R, Nagendra L, Bhattacharya S

Medicine1 Dec 2025Cited by 8 (Europe PMC)

PMID41398803PMCIDPMC12708229DOI10.1097/md.0000000000046446PepBankPUB-41398803

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced body weight by 3.27% from baseline at 3 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to a small weight loss after 3 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 3 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
MD body weight
−3.27%
3 months
Source sentences
Summary
Semaglutide use was associated with reductions in body weight from baseline at 3 months (MD -3.27% [-6.07 to -0.47]), 6 months (MD -6.53% [-8.44 to -4.63]), and 12 months (MD -7.6% [-8.16 to -7.04]).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880301
02HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced body weight by 6.53% from baseline at 6 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to weight loss after 6 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 6 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
MD body weight
−6.53%
6 months
Source sentences
Summary
Semaglutide use was associated with reductions in body weight from baseline at 3 months (MD -3.27% [-6.07 to -0.47]), 6 months (MD -6.53% [-8.44 to -4.63]), and 12 months (MD -7.6% [-8.16 to -7.04]).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880302
03HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced body weight by 7.6% from baseline at 12 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to weight loss after 12 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 12 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
MD body weight
−7.6%
12 months
Source sentences
Summary
Semaglutide use was associated with reductions in body weight from baseline at 3 months (MD -3.27% [-6.07 to -0.47]), 6 months (MD -6.53% [-8.44 to -4.63]), and 12 months (MD -7.6% [-8.16 to -7.04]).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880303
04HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced glycated hemoglobin by 0.54% from baseline at 3 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to a lower HbA1c after 3 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at 3 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
MD HbA1c
−0.54%
3 months
Source sentences
Summary
There was also a reduction in glycated hemoglobin from baseline at 3 months (MD -0.54% [-0.62 to -0.46]), 6 months (MD -0.55% [-0.71 to -0.40]), and 12 months (MD -0.6% [-0.72 to -0.48]).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880304
05HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced glycated hemoglobin by 0.55% from baseline at 6 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to a lower HbA1c after 6 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at 6 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
MD HbA1c
−0.55%
6 months
Source sentences
Summary
There was also a reduction in glycated hemoglobin from baseline at 3 months (MD -0.54% [-0.62 to -0.46]), 6 months (MD -0.55% [-0.71 to -0.40]), and 12 months (MD -0.6% [-0.72 to -0.48]).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880305
06HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced glycated hemoglobin by 0.6% from baseline at 12 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to a lower HbA1c after 12 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at 12 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
MD HbA1c
−0.6%
12 months
Source sentences
Summary
There was also a reduction in glycated hemoglobin from baseline at 3 months (MD -0.54% [-0.62 to -0.46]), 6 months (MD -0.55% [-0.71 to -0.40]), and 12 months (MD -0.6% [-0.72 to -0.48]).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880306
07HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced total daily insulin dose at 3 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to a lower daily insulin dose after 3 months.
Peptide
Semaglutide
Outcome
DecreaseTotal daily insulin dose at 3 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
MD insulin dose
−0.05 units/kg/d
3 months
Source sentences
Summary
Three months (MD -0.05 units/kg/d [-0.06 to -0.03]) and 6 months (MD -0.07 units/kg/d [-0.13 to -0.01]) but not 12 months (MD -0.00 units/kg/d [-0.06 to 0.05]) of semaglutide therapy were associated with a reduction in total daily dose of insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880307
08HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced total daily insulin dose at 6 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to a lower daily insulin dose after 6 months.
Peptide
Semaglutide
Outcome
DecreaseTotal daily insulin dose at 6 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
MD insulin dose
−0.07 units/kg/d
6 months
Source sentences
Summary
Three months (MD -0.05 units/kg/d [-0.06 to -0.03]) and 6 months (MD -0.07 units/kg/d [-0.13 to -0.01]) but not 12 months (MD -0.00 units/kg/d [-0.06 to 0.05]) of semaglutide therapy were associated with a reduction in total daily dose of insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880308
09HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed no significant change in total daily insulin dose at 12 months of semaglutide.
In plain wordsIn adults with type 1 diabetes and overweight, daily insulin dose was not clearly lower after 12 months of semaglutide.
Peptide
Semaglutide
Outcome
No significant changeTotal daily insulin dose at 12 months
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
MD insulin dose
0 units/kg/d
12 months
Source sentences
Summary
Three months (MD -0.05 units/kg/d [-0.06 to -0.03]) and 6 months (MD -0.07 units/kg/d [-0.13 to -0.01]) but not 12 months (MD -0.00 units/kg/d [-0.06 to 0.05]) of semaglutide therapy were associated with a reduction in total daily dose of insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880309
10HumanSystematic reviewSafety outcome
In adults with type 1 diabetes and overweight or obesity, adverse event data for semaglutide were scarce and mostly gastrointestinal.
In plain wordsIn adults with type 1 diabetes and overweight, few side effect data were reported for semaglutide, and most were stomach and gut related.
Peptide
Semaglutide
Outcome
Direction not reportedAdverse events
Study
n: not reported in source
Analysis
Secondary
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Adverse event data were scarce and mostly gastrointestinal.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880312
11HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide increased time in range by 4.62% at 3 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to more time with blood sugar in range after 3 months.
Peptide
Semaglutide
Outcome
IncreaseTime in range at 3 months
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
MD time in range
4.62%
3 months
Source sentences
Summary
Time in range (MD 4.62% [0.85 to 8.39]) and time above range (MD -8.97% [-16.41 to -1.53]) improved after 3 months of semaglutide use.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880310
12HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled data showed semaglutide reduced time above range by 8.97% at 3 months.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide was linked to less time with high blood sugar after 3 months.
Peptide
Semaglutide
Outcome
DecreaseTime above range at 3 months
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
MD time above range
−8.97%
3 months
Source sentences
Summary
Time in range (MD 4.62% [0.85 to 8.39]) and time above range (MD -8.97% [-16.41 to -1.53]) improved after 3 months of semaglutide use.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed.
Report a problemFND-4139880311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.

Summary

Results from this study12

Version history

Subjects

Publication types

MeSH terms

Keywords